Orphan Drug Pricing in France: Influence of Main Factors

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.1702
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pmu32 - Orphan Drug Prices in Europe: Impact of External Reference Pricing

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prm7 Drug Development and Pharmaceutical Pricing in the United States: The Influence of Drug Intended Outcomes of Drug Pricing

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Php243 - Do Disease Severity and/or Quality of Clinical Data Influence Pricing Policy in France? An Analysis on Orphan Drugs and Blood Cancers Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pmd160 - Pricing of Reimbursed Medical Devices in France: What Factors Impact Decision-Making?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Interrelated Factors Influence of Current Stock Market on Pricing

ScienceRise
2015English

Determinants of Orphan Drugs Prices in France: A Regression Analysis

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2017English

Rarefied Drug Pricing

Nature Biotechnology
Applied MicrobiologyBiotechnologyBiomedical EngineeringMolecular MedicineBioengineering
2014English

Drug Pricing and Value in Oncology

Oncologist
Cancer ResearchMedicineOncology
2010English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy